Google-backed, AI-developed drugs are headed to trial by 2026, DeepMind CEO says
Posted: Jan 24, 2025
- Researchers are using generative artificial intelligence to discover new ways to treat diseases
- Drugs developed by Alphabet's subsidiary Isomorphic Labs and designed by AI are expected to head to trial by the end of the year
- Isomorphic Labs is working with Eli Lilly & Co. and Novartis to use AI technology to discover therapeutics against multiple targets
- Other companies like Insilico Medicine are also working on AI-designed drugs and have sent one drug to clinical trials with positive results
Stay ahead of the market with AI stock alerts & AI summaries of the latest earnings, stock ideas for free with Fluid Bot. Sign up now!